PRAKASH MASAND to Piperazines
This is a "connection" page, showing publications PRAKASH MASAND has written about Piperazines.
Connection Strength
1.480
-
Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Int Clin Psychopharmacol. 2014 Mar; 29(2):116-9.
Score: 0.404
-
Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. Schizophr Res. 2011 Mar; 126(1-3):174-83.
Score: 0.324
-
Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010). Psychopharmacol Bull. 2008; 41(2):12-23.
Score: 0.263
-
Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord. 2019 10 01; 257:600-606.
Score: 0.146
-
A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. J Clin Psychopharmacol. 2015 Jun; 35(3):319-23.
Score: 0.110
-
Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013 Nov-Dec; 36(6):223-38.
Score: 0.099
-
A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4):e34757.
Score: 0.089
-
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002 Sep; 14(3):175-82.
Score: 0.046